MK-1293 shows non-inferiority to Lantus in two Phase III studies
Merck, known as MSD outside of the US and Canada, has announced results from two Phase III studies evaluating MK-1293 for the treatment of people with type 1 and type 2 diabetes.
In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus (insulin glargine) after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore, in both studies, MK-1293 met its pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, a measure used to show that an investigational treatment is similar, within an acceptable range, to a current therapy.
Click on this link for more information.